Retatrutide

GLP-1/GIP/Glucagon Triple Receptor Agonist

39 Amino Acids · MW: ~4,500 Da

Ask AI About This

Amino Acids

Molecular Weight

~4,500 Da

Half-life

~6 days

Research Score

4.6

Studies

Storage

N/A

What is Retatrutide?

Retatrutide is a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase II trials, it achieved up to 24% body weight loss, surpassing both semaglutide and tirzepatide. It represents the next evolution in incretin-based therapies.

Key Benefits & Mechanisms

Unprecedented weight loss (up to 24% in trials)

Triple receptor activation

Superior to dual agonists

Significant metabolic improvements

Reduced liver fat

Improved cardiovascular markers

Enhanced insulin sensitivity

Research Summary

Retatrutide Phase II trial (TRIUMPH-2) showed 24.2% mean body weight loss at 48 weeks, the highest of any anti-obesity medication in clinical development. Currently in Phase III trials. Could represent a paradigm shift in obesity treatment if approved.

Related Peptides

Semaglutide

GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.

Metabolic

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.

Metabolic

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

Tesamorelin

Synthetic Growth Hormone Releasing Hormone

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.

Metabolic